ZLDI-8

ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM[1][2].

Product Specifications

CAS Number

[667880-38-8]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis; Notch; Phosphatase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Neuronal Signaling; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zldi-8.html

Purity

98.47

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(/C(C(N1)=O)=C/C2=C(C)N(CCOC3=CC=C(C)C=C3C)C4=C2C=CC=C4)NC1=S

Molecular Formula

C24H23N3O3S

Molecular Weight

433.52

Precautions

H315, H319

References & Citations

[1]Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9 (7) :743.|[2]Hou X, et al. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014 Nov 26;57 (22) :9309-22.